IN 1985, Reed et al1 published the first case series of subacute cutaneous lupus erythematosus (SCLE) that was linked to the administration of a drug. They reported that the onset of the cutaneous eruption occurred during the administration of hydrochlorothiazide treatment and resolved with its discontinuation. In addition, 1 of their patients was treated with a second administration of hydrochlorothiazide that was followed by a reappearance of the eruption, which then cleared again with discontinuation of treatment with the offending drug. Their patients were anti-Ro/SSA positive, and in 1 of the 3 patients subsequently tested, the antibody disappeared.